Member Info for Aldebaran

Its not 5m though is it its 6m or so after costs and if the SP continues to drop the dilution will be greater and greater the lower it goes

Quick recap

I said at 7m market cap company was at risk of delisting.

I said if price brakes 180p with volume or funding news comes then that would be a buy signal which it was

I said resistance would be 1600p which it was

I said price would pullback initially to around 1000p which it did.

I said that first batch of warrants hadn't been forward sold which was proved to be correct

Ive calculated that its highly unlikely the warrants landing on the 24th have all been forward sold and im sure ill be proven correct.

I said BP won't do a deal off 3 patients and that was correct

I said cash burn would increase to around 500k per month with us treating 2 patience per month which turned out correct

Im now saying price will test 500p but yall dont want to hear that so its dismissed. Tbh this incoming placing could see it fall further than that but as ever we will see what price action tells us.

Right now despite a slight rebound in low volume I expect this to fall and if anyone truly disagreed confidently then you know where IG is... go make a fortune 👍

You knew we would "attack the company" good lord have you heard yourself.

If you knew yesterday about this 5.6m funding requirement why not bring it up for discussion? I admit I didnt read the prospectus so was pleased when NP highlighted this issue. Why didnt you? If you "knew" we would "attack" the company?

Dramatic to say the least. Im gobsmacked that the cash as run out so quick. I was expecting 500k cash burn though which YOU denied weeks ago. And said I was misinformed etc

Dilutive sources would be falling over themselves to use leverage but no. Lol

He says one thing and does another. Trust no one not even me just do your own research

This is called a dead cat bounce btw.

JHFH doesnt really believe this is the bottom otherwise he would of put his house on a leveraged trade.

Especially with the insider information he has, not concerned about were the 6m+ funds after costs are coming from in jan. Surely anyone that truly believes were at a bottom and knows there's easily going to be 6m+ coming into the company from non

JHFH if you really truly believed this was the bottom why not use leverage?

Just like when you took part in the placings if you really thought they were at such a bargain price why insist on 1 for 1 warrants?

Perhaps your not as naive as I first thought you were.

Perhaps you are actually secretly selling into strength etc like the other guy keeps saying

If there was enough data for big farmer insiders would be buying and a deal would have been done. Even at the 2 recent dealmaking events nothing came for hemo despite the cult leaders trying to ramp it saying Congress people would be queuing up to see Vlad.

So comfortable truth 1 is that there is not enough data for a deal.

Comfortable truth 2 is that the company have confirmed they need £5.6m by end Jan latest.

Comfortable truth 3 is that this money is ONLY to progress HG-CT-1 so you can forget about CDX/CBR unless company plan to raise even more than that

Comfortable truth 4 is that if Hemo need this amount, they'll need more than that as have to factor in costs.

Comfortable truth 5 a placing is required and it will be offered with warrants increasing dilution further.

Comfortable truth 6 if JHFH and his mates had over 6m they would or should have took company private last summer

Comfortable truth 7 avacta is going 100x within next 12 months. It as cash and better management better science bigger market opportunity. Do some research on a proper biotech and you might learn a few things

Now fully out after selling 50% at 1600p and being derided for it by the cult.

I may buy back in after the placing at a discount and get a load of warrants to boot. It'll be rude not to.

For anyone unsure wear this statement comes from it is here

Investors – Hemogenyx Pharmaceuticals https://hemogenyx.com/investors/

Scroll down to the latest prospectus and look at page 7. Its there in black and white.

As i say I did estimate 500k would be our cash burn (was obviously scoffed at by the cult) but what as surprised me is the urgency with which the money is needed. January just doesn't leave much time with Christmas and new year approaching.

What is Vlad going to do? I can't see past us being back to monthly placings and confetti sprinklings at best.

Theirs just no way we'll have enough data for a farmer deal in time. Clearly what they have already isn't enough.

Any idea when tech transfer will complete anyone??

No of course not. We're completely in the dark just as JHFH and others like it 😅

Because precision is so broadly applicable to 90% of solid tumours and were can release multiple warheads in the tumour microenvironment not just chemotherapy it means that precision impacts revenues of almost if not all big pharma. These revenues run into 10's of billions.

As soon as one moves the others HAVE to move. Its not like this is a novel target with a novel drug. FAP is expressed in 90% of solid tumours and our delivery peptide has proven it is capable of carrying multiple payloads

Chill out time in my view. Feet up

For me, if there was big pharma interest off 3 patients data like Haywain said there would be and the patients are still alive then a deal would be done.

Clearly thats not the case so best thing now is big pharma want to see next cohort including pediatrics before making a commitment. Thats best case.

When will that be? Given tech transfer not even complete let alone patient recruitment then dosing and then waiting 28 days for safety data then waiting months to prove durability its impossible for any kind of farmer deal before cash runs out in January.

So it will have to be a fire sale on shhh it terms OR further placing. If they go for the full 5.6m then that's shareholders wiped out. Again. If they try and limp on with monthly raises by JHFH and his mates then it puts them in poor negotiation position with big pharma.

Its a complete mess in my view.

Why oh why was a fundraise not planned and executed off the back of last spike. Vlad has to step down his position is untenable.

As ive said, its about more than just the science

I did say that tech transfer was taking much longer than it previously did, is it because MADE were waiting for payment? I dont understand surely before the process was started the costs were agreed. It just seems a mess to me.

Of course there are some long term holders who had zero idea of prior tech transfers and they call themselves the clued up ones branding me and others idiots. Talk about dunning krueger

Shambles

Pumpkin it will either have to be a fire sale so investors can forget these 1 gazillion valuations or they'll most likely try and raise monthly again. 500k a month though which is a big ask. Of course the monthly placings will come with warrants.

Given how JHFH and the gang are guiding Vlad to operate I am staggered they didnt take company private at 7m market cap. I suspect if they had the money too then they would which tells me they dont have that kind of money so we're is it going to come from. Limping on maybe for a few months then potentially going to big farmer begging for a deal isnt likely to produce the outcome shareholders here are expecting.

As i said before but was shot down vlad had visibility of all the news and knew price would rise, he also knew cash burn was going to increase massively as trials progressed and so he should of had the foresight to do a raise off the back of the last spike.

A lot as been said that this isnt the same old hemo but evidence says otherwise. What a mess.

Total and complete failure on the part of CEO who needs to take a back seat and run the trials allowing a commercially savvy CEO to take the reigns.

Thank God I have the bulk of my money tied up in a proper biotech with less risk, greater potential upside, proper management team and a clear plan which is delivering for shareholders and patience

Nobody is trying to bring the company down, not be discussing latest news on here lol.

Anyway, I downloaded the prospectus to grok and asked AI to analyse it, make a simple summary and tell me what to expect from hemo between now and end 2026. A simple prompt and this is the response

**Simple Summary of Hemogenyx's Prospectus (19 November 2025)

This is a regulatory document (a "simplified prospectus") required because Hemogenyx is listing 556,611 new ordinary shares on the London Stock Exchange's Main Market (starting 24 November 2025). These new shares come from:

Converting loan notes (116,982 shares).

Exercising warrants (439,629 shares already exercised or to be exercised).

It's not a big fundraising — just cleaning up existing obligations. The company isn't raising new cash here.

Financial Health (Red Flags)

Cash is critically low: Only £226k in the bank as of June 2025.

Burning money fast: Lost ~£5 million in the first half of 2025 alone (mostly R&D and admin).

Going concern warning: Auditors say the company will run out of money in Q1 2026 and needs fresh funding soon just to keep going and finish the adult + paediatric Phase 1 trial of HG-CT-1 (CAR-T for r/r AML).

They will definitely need to raise more money in early 2026 (likely another big placing or convertible loans).

What to Expect from Now Until End of 2026

Short term (Nov 2025 – March 2026): Survival mode

Possible small updates on the ongoing Phase 1 trial (e.g., more patients dosed at higher level, safety data).

High chance of a fundraise (new shares issued at a discount) before cash runs out — this usually causes short-term share price pain.

ASH conference (December 2025) could have updated data (e.g., durability in first patients, early look at higher dose).

Mid 2026: Key clinical milestones

Finish Phase 1 adult trial (dose escalation, ~18–24 patients total).

Start or expand paediatric part of the trial (already FDA-cleared).

If data stays strong (so far 3/3 patients with complete remission or undetectable cancer), this is when serious pharma partnership / licensing talks could heat up.

Possible "hospital exemption" revenue in Estonia (via Cellin deal) — very small at first, but first real income.

End 2026 outlook

Best case: Phase 1 fully done, strong safety + efficacy → major partnership or buyout offer (hundreds of millions valuation possible if HG-CT-1 looks curative in AML).

Base case: Another fundraise, slow progress into Phase 2 planning, share price volatile.

Worst case: Trial setbacks or cash crisis → heavy dilution or restructuring.

Bottom line: 2026 is make-or-break. The company has promising early CAR-T data in a terrible disease (r/r AML), but it's almost out of money. Expect at least one fundraise and big news swings tied to trial results. If the science keeps working, a deal could transform the company; if not, more painful dilution. High risk/high reward classic small-cap biotech story.**

Soooo is Grok also trying to

I dont no who dr hull is or why he is supposedly a big deal. I dont care who buys or sells or issues tr1 it is irrelevant. Same as who is putting a short on. What i care about is hemo and the fact their telling the market they need 5.6m by Jan. Which is 467k per month (wasn't to far of with my 500k prediction was i).

This will be spent primarily on HG-CT-1 which is absolutely the right thing but it means CBR CDX are on the backburner. Estonia. Its a non binding letter of intent. During last interview vlad didnt know if or when anything material there would come so im writing that off.

He didnt know how long tech transfer would take as I spelt out for you its already been longer than last time. He didnt give guidance on anything all he did clarify was "obviously hemo need a lot more cash" and then this prospectus drops confirming how much.

Funny how he can be extremely specific about the funding but clueless about anything else when asked.

5.6m needed to sign the accounts off, even despite all the warrant and CLN money? Yall can ramp this hard as you like. That does not look good to me.

Of course there IS a proper company who are in a uptrend, have just raised 16m at less than 10% discount and on the verge of re-rating news... id take a serious look at Avacta a 100 bagger in plane sight.

Hemo is just not at its inflexion point yet. Nowhere near seemingly

I said last week or week before that cash burn here would be increasing to around 500k per month did I not? I worked out the cost of manufacturing CAR-T applied some other factors like inflation and PLC costs and came to 500k per month and I was absolutely torn to bits by the cult, again. Derided even and laughed at accused of deramping being stupid etc etc.

Now today we have the following from JHFH "Not sure what you think tye "win" is lol, 15mil over several years to complete a trial if no license? Yea... 5m to complete 2026? That's less than 500k a month whilst in trials. Again. I refer you to the following post:"

You lot are comedy gold for me. Low IQ to say the least. You only see things when they are spelt out for you or with hindsight.

So 500k per month cash burn then. How is that getting funded, have JHFH and his mates got that kind of cash? Will they be demanding more warrants at each monthly placing?

I also said there as been a tech transfer previously here and was poked fun at and dismissed by one of the cult members who has yet to show any humility or class and apologise after I proved there had been.

Ive researched this stock better than most LTH it seems and I continually am making correct calls. Not so much of a fool now am i

Things whizzing along now on the back of a 4 year phase 1 trial let's not forget we did have the cardio issue for one person which meant trial had to be halted. Later turned out it was nothing to do with 6k.

Then remember 6k was a new Molecular entity so uptake was slow and of course initially only in the UK without USA branches and then remember that no MTD was found because the PDC is so exquisitely cleaved by FAP. All in all p1a was a huge success scientifically and now the data we have and confidence will help derisk and expedite the next trial phases.

Plus we have USA sites open and the likes of MD Anderson claiming they cant wait to get trials going, we have clinicians saying they believe 6k should be standard of care, we have trials informed by Tempus AI and all the relationships between trial sites and regulators all in place. All built on the rock solid foundation of ava6k p1a.

I cant think if a small biotech that wouldn't want to swap places with Avacta right now

Lol thanks I think

If you read my post it clearly says 5x volume comes from my experience of having a placing every 3 months at avacta for years. Plus other stocks.

Can you not read? Or do you just have low IQ? probably both

You assume whatever you like jhfh as ive said your always right. No I didnt make any numbers up i looked at the warrants issued and tried to match them up .ultimately the number of warrants issued plus cln shares and the number outstanding are the only facts we have. We're all guessing the bits in between

Usually shares take 5x the volume to clear and I know all about that with avacta having a placing every quarter lol

Ive then taken time to calculate the volume traded since the decline in value started and made what I belief to be a educated guess that the warrants haven't all been forward sold.

You've said they've all been forward sold, based on what?

Hopium?

The fact there as been a momentary pause in selling?

Nothing?

At least I give reason behind my thinking whether it be TA or otherwise. You lot just ramp the backside of this all day every day.

Hemotruth, didn't even realise there as been previous tech transfer. Embarrassing from a self proclaimed LTH.

Like I said, its a low IQ board this one